Results 181 to 190 of about 12,217,563 (347)
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Gravity beyond starch: molecular evidence for a parallel gravity sensing mechanism. [PDF]
McNelly R, Depaepe T.
europepmc +1 more source
Scaling single-cell genomics from phenomenology to mechanism
A. Tanay, A. Regev
semanticscholar +1 more source
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee +8 more
wiley +1 more source
Correction: Unlocking the adenosine receptor mechanism of the tumour immune microenvironment. [PDF]
Han Y, Dong C, Hu M, Wang X, Wang G.
europepmc +1 more source
CD28 Costimulation: From Mechanism to Therapy.
Jonathan H. Esensten +4 more
semanticscholar +1 more source
Tumor mutational burden as a determinant of metastatic dissemination patterns
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal +4 more
wiley +1 more source
An emerging clock mechanism in a hydrozoan jellyfish. [PDF]
Rosato E.
europepmc +1 more source
The Radical-Pair Mechanism of Magnetoreception.
P. Hore, H. Mouritsen
semanticscholar +1 more source
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source

